

PERSONAL INFORMATION

Maria Concepcion Prieto Yerro

WORK EXPERIENCE

-
- 2005- Present **Technical adviser for the Department of Drugs for Human Use**
Spanish Agency for Drugs and Medical Devices (Spain)
Head of the Centralised Procedure Unit (coordinating all activities related to the centralised procedure applications)
CHMP member from Spain
- 2001- 2005 **Head of Service of Clinical Assessment and Pharmacology**
Spanish Agency for Drugs and Medical Devices (Spain)
Clinical assessor (Cardiovascular, SNC, ophtalmology, lung diseases, urology)
- 1994- 1996 **Coordinator of the Program of Rational of Drugs in Primary Care**
National Health Service - Primary Care - Sector 4 Madrid (Spain)
Drug information activities
- 1992- 1994 **Assessor of the Department of Health Promotion**
National School of Health (Spain)
Health education, health promotion, use of drugs
- 1990- 1992 **Assessor of the Division of Pharmaceutical Provision**
Ministry of Health - Madrid (Spain)
Development and implementation of the Program of Rational Use of Drugs in Primary Care
- 1985- 1990 **General practitioner - Primary care**
National Health Service (Spain)
Clinical practice in primary care

EDUCATION AND TRAINING

-
- 1977- 1984 **Degree in Medicine and Surgery (MD), 1984**
School of Medicine. Universidad Complutense de Madrid (Spain)
Medicine and Surgery
- 1994- **PhD (Doctorate), 1994**
Universidad Autónoma de Madrid - Spain (Spain)
Rational Use of Drugs in Primary Care
- 1996- 2000 **Specialist in Clinical Pharmacology**
Hospital Universitario Clínico de San Carlos- Madrid (Spain)
Two years of rotations in internal medicine, haematology, nephrology and neurology units. Four years as duty doctor in emergency department. Four-year training in matters related to clinical pharmacology issues (drug utilisation studies, drug monitoring...)

ADDITIONAL INFORMATION

-
- Expertise Ophthalmology
Radiopharmaceutical products
Clinical Pharmacology
SNC
Respiratory

Publications

- 1.- Prieto Yerro C, Lopez Corbalan JC. Utilizacion de antihipertensivos en Baleares y su analisis comparativo en el periodo 1981-86. *Inf Ter Segur Soc* 1988; 12:97-9
- 2.- Garcia Inesta A, Prieto Yerro C. Utilizacion de antiinfecciosos en Espana en el periodo 1981-1987. *Inf Ter Segur Soc* 1988;12:181-92
- 3.- Inesta A, Prieto Yerro C. Utilizacion de cloranfenicol en el periodo 1982-1987. *Inf Ter Segur Soc* 1989;13:148-59
- 4.- Prieto I, Prieto C, Sacristan A. Utilizacion de analgesicos narcoticos en el tratamiento del dolor. *Inf Ter Sist Nac Salud* 1991;15:180-6
- 5.- Cortes E, Cuesta T, Ferre P, Rodriguez A, Prieto C. Nuevos principios activos comercializados en Espana en 1991. *Inf Ter Sist Nac Salud* 1992;16(4):79-95
- 6.- Sacristan Rodea A, Terol Garcia E, Prieto Yerro C. Estudio de un programa de cuidados paliativos a domicilio. *Atencion Primaria. Area 4 del INSALUD. Madrid.* 1996
- 7.- Palanca Sanchez I, Prieto Yerro C, Sacristan Rodea A. Prestacion y politicas farmaceuticas. La salud y los servicios sanitarios en la Comunidad de Madrid. *AMA* 1996:327-333
- 8.- Garcia Arenillas M, Prieto Yerro C, Portoles Perez A. Utilizacion de medicamentos en el embarazo, lactancia, ninos y ancianos. *Medicine* 1999;130:6158-66
- 9.- Moreno Gonzalez A, Vargas Castrillon E, Gassent Balaguer C, Laredo Velasco L, Prieto Yerro C. Guia farmacologica en podologia. *Federacion Espanola de Podologos. Madrid,* 1999
- 10.- Prieto Yerro C, Vargas Castrillon E. Uso de AINE en pacientes con patologia cronica asociada. *Inf Ter Sist Nac Salud* 2000;24(4):85-91
- 11.- Prieto Yerro C, Perez Lopez C, Rodriguez Bernardino A, Martinez Martinez R, del Potro Gomez E, Alvarez Carmona A. Relapsing pancytopenia following exposure and re-exposure to cyanamide. *Eur J Haematology* 2000;65:1-2
- 12.- Prieto Yerro C, Vargas Castrillon E, Laredo Velasco L, Perez-Cecilia E, Ambit Avila I, Picazo de la Garza JJ. Utilizacion de Anfotericina B no convencional en el hospital Clinico de San Carlos. *Rev Esp Salud Publica* 2000;74:345-53
- 13.- Prieto Yerro C, Rodriguez Bernardino A, Vargas Castrillon E. Utilizacion de propacetamol en el Hospital Clinico de San Carlos. *Atencion Farmaceutica* 2000; 2(6): 534-8
- 14.- Prieto Yerro C, Vargas Castrillon E, Laredo Velasco L, Perez-Cecilia E, Ambit Avila I, Picazo de la Garza JJ. Modificacion en el patron de uso de anfotericina B no convencional tras una intervencion formativa en el hospital Clinico de San Carlos. *Rev Esp Salud Publica* 2001;75(2):353-60
- 15.- Moreno Gonzalez, A; Prieto Yerro, C; Vargas Castrillon, E, Laredo Velasco, L, Asenjo Correa, S. Profilaxis del tromboembolismo venoso en paciente no quirurgicos. *Medifam* 2002; 12 (6): 369-378
- 16.- M Berntgen, H. Enzmann; E. Schabel, C. Prieto Yerro, A. Gomez-Outes, T. Samonson, J. Musaus. Linaclotide for treatment of irritable bowel syndrome-The view of the European regulators. *Dig Liver Dis.* 2013 Sep;45(9):724-6.
- 17.- Cortes-Blanco A, Prieto Yerro C, et al. Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval. *Alzheimer's and Dementia* 2014;10 (5): S395-S399.
- 18.- Haas M, Prieto Yerro C et al. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchene muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. *Neuromuscular disorder* 2015; 25 (1): 5-13
- 19.- de Wit M, Cooper C, Tugwell P, Bere N6, Kirwan J, Conaghan PG, Roberts C, Aujoulat I, Al-Daghri N, Araujo de Carvalho I, Barker M, Bedlington N, Brandi ML, Bruyere O, Bulet N, Halbout P, Hilgismann M, Jiwa F, Kanis JA, Laslop A, Lawrence W2, Pinto D, Prieto Yerro C, Rabenda V, Rizzoli R, Scholte-Voshaar M, Vlaskovska M, Reginster JY. Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Aging Clinical and Experimental Research* 2019; 31(7), 905-915
- 20.- Jean-Yves Reginster et al. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. *Aging Clinical and Experimental Research* 2020, Jul 31. <https://doi.org/10.1007/s40520-020-01663-4>

Projects

Memberships

From 2005-2010 alternate at the CHMP from Spain.

From 2003-2006 member of the Ethics Committee of University Hospital of Mostoles (Madrid, Spain).

From 2013 member of the Patients' and Consumers' Working Party.

From 2016 member of the Respiratory Drafting Group.

Member of the Spanish National Board on Human Medicines.

Peer Reviewer for the "Revista Espanola de Salud Publica".

Other Relevant Information

Master's degree in Methodology of the Investigation (400 h)